TMEM135

Across TCGA pan-cancer cohorts, TMEM135 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM135 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM135 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM135 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where TMEM135 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.999	0.838	.003	22	view →
PDAC	OS	Quartile	All	0.411	0.634	.015	8	view →
UCEC	DFS	Quartile	All	0.698	1.000	.025	4	view →
LUAD	OS	Median	III,IV	0.764	0.232	.009	3	view →
HNSC	OS	Median	IV	0.864	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM135–CCRCC (DFS)

Open the CCRCC breakdown →